95 related articles for article (PubMed ID: 15879877)
1. CD70: a new tumor specific biomarker for renal cell carcinoma.
Junker K; Hindermann W; von Eggeling F; Diegmann J; Haessler K; Schubert J
J Urol; 2005 Jun; 173(6):2150-3. PubMed ID: 15879877
[TBL] [Abstract][Full Text] [Related]
2. CD70 is Consistently Expressed in Primary and Metastatic Clear Cell Renal Cell Carcinoma.
Huang RR; Chen Z; Kroeger N; Pantuck A; Said J; Kluger HM; Shuch B; Ye H
Clin Genitourin Cancer; 2024 Apr; 22(2):347-353. PubMed ID: 38195301
[TBL] [Abstract][Full Text] [Related]
3. Stimulated Raman histology as a method to determine the adequacy of renal mass biopsy and identify malignant subtypes of renal cell carcinoma.
Mannas MP; Deng FM; Belanger EC; Jones D; Ren J; Huang W; Orringer DA; Taneja SS
Urol Oncol; 2023 Jul; 41(7):328.e9-328.e13. PubMed ID: 37225634
[TBL] [Abstract][Full Text] [Related]
4. Absolute quantitative proteomics using the total protein approach to identify novel clinical immunohistochemical markers in renal neoplasms.
Jorge S; Capelo JL; LaFramboise W; Satturwar S; Korentzelos D; Bastacky S; Quiroga-Garza G; Dhir R; Wiśniewski JR; Lodeiro C; Santos HM
BMC Med; 2021 Sep; 19(1):196. PubMed ID: 34482820
[TBL] [Abstract][Full Text] [Related]
5. Potential of adhesion-regulating molecule 1 (ADRM1) as a biomarker for patients with renal clear-cell carcinoma or papillary-cell carcinoma.
Zhu D; Zhong Q
Asian J Surg; 2023 Oct; 46(10):4666-4668. PubMed ID: 37268471
[No Abstract] [Full Text] [Related]
6. The specificity of urinary aquaporin 1 and perilipin 2 to screen for renal cell carcinoma.
Morrissey JJ; Kharasch ED
J Urol; 2013 May; 189(5):1913-20. PubMed ID: 23154208
[TBL] [Abstract][Full Text] [Related]
7. Re: CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma.
Jiang A; Liu Y; Lin A; Luo P; Wang L
Eur Urol; 2024 May; ():. PubMed ID: 38735819
[No Abstract] [Full Text] [Related]
8. CD70 expression patterns in renal cell carcinoma.
Jilaveanu LB; Sznol J; Aziz SA; Duchen D; Kluger HM; Camp RL
Hum Pathol; 2012 Sep; 43(9):1394-9. PubMed ID: 22401771
[TBL] [Abstract][Full Text] [Related]
9. Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma.
Tannir NM; Forero-Torres A; Ramchandren R; Pal SK; Ansell SM; Infante JR; de Vos S; Hamlin PA; Kim SK; Whiting NC; Gartner EM; Zhao B; Thompson JA
Invest New Drugs; 2014 Dec; 32(6):1246-57. PubMed ID: 25142258
[TBL] [Abstract][Full Text] [Related]
10. pVHL/HIF-regulated CD70 expression is associated with infiltration of CD27+ lymphocytes and increased serum levels of soluble CD27 in clear cell renal cell carcinoma.
Ruf M; Mittmann C; Nowicka AM; Hartmann A; Hermanns T; Poyet C; van den Broek M; Sulser T; Moch H; Schraml P
Clin Cancer Res; 2015 Feb; 21(4):889-98. PubMed ID: 25691774
[TBL] [Abstract][Full Text] [Related]
11. CD70: An emerging target in cancer immunotherapy.
Jacobs J; Deschoolmeester V; Zwaenepoel K; Rolfo C; Silence K; Rottey S; Lardon F; Smits E; Pauwels P
Pharmacol Ther; 2015 Nov; 155():1-10. PubMed ID: 26213107
[TBL] [Abstract][Full Text] [Related]
12. Targeting pancreatic and ovarian carcinomas using the auristatin-based anti-CD70 antibody-drug conjugate SGN-75.
Ryan MC; Kostner H; Gordon KA; Duniho S; Sutherland MK; Yu C; Kim KM; Nesterova A; Anderson M; McEarchern JA; Law CL; Smith LM
Br J Cancer; 2010 Aug; 103(5):676-84. PubMed ID: 20664585
[TBL] [Abstract][Full Text] [Related]
13. CD70 (TNFSF7) is expressed at high prevalence in renal cell carcinomas and is rapidly internalised on antibody binding.
Adam PJ; Terrett JA; Steers G; Stockwin L; Loader JA; Fletcher GC; Lu LS; Leach BI; Mason S; Stamps AC; Boyd RS; Pezzella F; Gatter KC; Harris AL
Br J Cancer; 2006 Aug; 95(3):298-306. PubMed ID: 16892042
[TBL] [Abstract][Full Text] [Related]
14. Identification of CD70 as a diagnostic biomarker for clear cell renal cell carcinoma by gene expression profiling, real-time RT-PCR and immunohistochemistry.
Diegmann J; Junker K; Gerstmayer B; Bosio A; Hindermann W; Rosenhahn J; von Eggeling F
Eur J Cancer; 2005 Aug; 41(12):1794-801. PubMed ID: 16043348
[TBL] [Abstract][Full Text] [Related]
15. Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates.
Law CL; Gordon KA; Toki BE; Yamane AK; Hering MA; Cerveny CG; Petroziello JM; Ryan MC; Smith L; Simon R; Sauter G; Oflazoglu E; Doronina SO; Meyer DL; Francisco JA; Carter P; Senter PD; Copland JA; Wood CG; Wahl AF
Cancer Res; 2006 Feb; 66(4):2328-37. PubMed ID: 16489038
[TBL] [Abstract][Full Text] [Related]
16. Expression of Potential Antibody-Drug Conjugate Targets in Cervical Cancer.
Mallmann MR; Tamir S; Alfter K; Ratiu D; Quaas A; Domroese CM
Cancers (Basel); 2024 May; 16(9):. PubMed ID: 38730739
[TBL] [Abstract][Full Text] [Related]
17. The novel high-affinity humanized antibody IMM40H targets CD70, eliminates tumors via Fc-mediated effector functions, and interrupts CD70/CD27 signaling.
Li S; Chen D; Guo H; Liu D; Yang C; Zhang R; Wang T; Zhang F; Bai X; Yang Y; Sun N; Zhang W; Zhang L; Zhao G; Peng L; Tu X; Tian W
Front Oncol; 2023; 13():1240061. PubMed ID: 37849799
[TBL] [Abstract][Full Text] [Related]
18. Antibody-Drug Conjugates for the Treatment of Renal Cancer: A Scoping Review on Current Evidence and Clinical Perspectives.
Sganga S; Riondino S; Iannantuono GM; Rosenfeld R; Roselli M; Torino F
J Pers Med; 2023 Aug; 13(9):. PubMed ID: 37763107
[TBL] [Abstract][Full Text] [Related]
19. Antibody-Based Therapeutics for the Treatment of Renal Cell Carcinoma: Challenges and Opportunities.
Mahmoud AM; Nabavizadeh R; Rodrigues Pessoa R; Garg I; Orme J; Costello BA; Cheville J; Lucien F
Oncologist; 2023 Apr; 28(4):297-308. PubMed ID: 36745503
[TBL] [Abstract][Full Text] [Related]
20. Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia.
Leick MB; Silva H; Scarfò I; Larson R; Choi BD; Bouffard AA; Gallagher K; Schmidts A; Bailey SR; Kann MC; Jan M; Wehrli M; Grauwet K; Horick N; Frigault MJ; Maus MV
Cancer Cell; 2022 May; 40(5):494-508.e5. PubMed ID: 35452603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
